ReviewPharmaceutical nanotechnology2022
Unravelling Micro and Nano Vesicular System in Intranasal Drug Delivery for Epilepsy.
Review in Pharmaceutical nanotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Intranasal Biodegradable Nanomedicine for Epilepsy Management: Targeting the Brain Beyond the Blood-Brain Barrier.International journal of nanomedicine · 2026Review
- Achieving Endo/Lysosomal Escape Using Smart Nanosystems for Efficient Cellular Delivery.Molecules (Basel, Switzerland) · 2024Review
- Collagen-Based Hydrogels for the Eye: A Comprehensive Review.Gels (Basel, Switzerland) · 2023Review
- "Bioinspired" Membrane-Coated Nanosystems in Cancer Theranostics: A Comprehensive Review.Pharmaceutics · 2023Review
- Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas.Pharmaceutics · 2023Review
- In Vivo Evaluation of Almotriptan malate Formulation through Intranasal Route for the Treatment of Migraine: Systematic Development and Pharmacokinetic Assessment.AAPS PharmSciTech · 2023Article
- Dual Targeting Anti-Osteoporotic Therapy Through Potential Nanotherapeutic Approaches.Pharmaceutical nanotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpilepsy is one of the major neurological disorders, affecting about 50 million people globally. Oral, intravenous and rectal delivery systems are available for the management of epileptic seizures. However, intranasal delivery serves as beneficial for delivering antiepileptic drugs owing to the advantages it offers.
objectiveVarious approaches have been developed over the years aiming to attain either a safer or faster brain delivery; a nasal delivery system proposes significant outcomes. The noninvasiveness and high vascularity contribute to the high permeability of the nasal mucosa, allowing rapid drug absorption. This review highlights some promising novel approaches to efficiently deliver anti-epileptic drugs by employing the nasal route.
methodsThe method includes a collection of data from different search engines like PubMed, ScienceDirect and SciFinder for obtaining appropriate and relevant literature regarding epilepsy, intranasal delivery of anti-epileptic agents, and novel therapeutics.
resultsThe present review underlines the majority of work related to intranasal delivery in the treatment of epilepsy, aiming to draw the attention of the researchers towards the easiest and most efficient ways of formulation for the delivery of anti-epileptics during seizures.
conclusionThis review intends to provide an understanding of the delivery aspects of antiepileptic drugs, the benefits of intranasal delivery and the novel approaches employed for the treatment of epilepsy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.